Cosunter(SZ:300436) Xin Lang Cai Jing·2025-12-02 03:19Core Viewpoint - Guangshentang experienced a decline of 5.01% on December 2, with a stock price of 94.54 CNY per share and a total market capitalization of 15.057 billion CNY [1] Company Overview - Fujian Guangshentang Pharmaceutical Co., Ltd. is located in Fuzhou, Fujian Province, and was established on June 28, 2001, with its listing date on April 22, 2015 [1] - The company's main business involves the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications and 1.46% from other supplementary products [1] Fund Holdings - Jin Xin Fund has one fund heavily invested in Guangshentang, specifically the Jin Xin Value Selection Mixed A (005117), which held 11,000 shares, accounting for 3.65% of the fund's net value, ranking as the eighth largest holding [2] - The fund has experienced a floating loss of approximately 54,900 CNY today [2] Fund Performance - Jin Xin Value Selection Mixed A (005117) was established on September 1, 2017, with a current scale of 13.4048 million CNY [2] - Year-to-date return is 52.18%, ranking 741 out of 8122 in its category; the one-year return is 47.38%, ranking 869 out of 8056; and since inception, the return is 70.76% [2] Fund Manager Information - The fund managers are Liu Shang and Tan Zhiming, with Liu having a tenure of 102 days and a total fund size of 109 million CNY, while Tan has a tenure of 237 days with a total fund size of 141 million CNY [3] - Liu's best and worst fund returns during his tenure are -7.2% and -14.03%, respectively, while Tan's best and worst returns are 33.16% and -2.98% [3]